Skip to main content

Research Repository

Advanced Search

Outputs (3)

Imidazoline compounds protect against interleukin 1beta-induced beta-cell apoptosis. (2001)
Journal Article
Zaitsev, S. V., Appelskog, I. B., Kapelioukh, I. L., Yang, S. N., Köhler, M., Efendic, S., …Maarabouni, M. (2001). Imidazoline compounds protect against interleukin 1beta-induced beta-cell apoptosis. Diabetes, 50(suppl_1), Article S70. https://doi.org/10.2337/diabetes.50.2007.s70

Imidazoline compounds have been considered for the treatment of type 2 diabetes. We have now investigated the effects of imidazolines on interleukin (IL)-1beta-induced beta-cell apoptosis and the signal transduction pathways involved. Inhibition of C... Read More about Imidazoline compounds protect against interleukin 1beta-induced beta-cell apoptosis..

Characterization of a K<inf>ATP</inf> channel-independent pathway involved in potentiation of insulin secretion by efaroxan (2001)
Journal Article
Chan, S. L., Mourtada, M., & Morgan, N. G. (2001). Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. Diabetes, 50(2), 340–347. https://doi.org/10.2337/diabetes.50.2.340

Efaroxan, like several other imidazoline reagents, elicits a glucose-dependent increase in insulin secretion from pancreatic β-cells. This response has been attributed to efaroxan-mediated blockade of KATP channels, with the subsequent gating of volt... Read More about Characterization of a K<inf>ATP</inf> channel-independent pathway involved in potentiation of insulin secretion by efaroxan.